Balthaser Kevin, Chief Financial Officer, has engaged in a consistent pattern of selling activity in shares of Aclaris Therapeutics, Inc. (ACRS), as evidenced by SEC Form 4 filings. Over 25 transactions spanning from January 2024 to March 2026, Kevin has exclusively sold shares, with no recorded purchases. The total value of these sales amounts to $125,856.26, reflecting a clear bias toward divestment rather than accumulation. Notably, the transactions are concentrated in ACRS, indicating Kevin’s focus on this single company. The largest single sale occurred on December 31, 2025, with shares valued at $60,001.34, followed by a $22,378.03 transaction on February 3, 2026. Smaller sales, such as $529.48 on March 2, 2024, and $677.50 on January 1, 2026, punctuate the timeline, suggesting a steady reduction in holdings. While the filings do not indicate recent activity—no trades were reported in the most recent period—the historical data underscores a consistent trend of selling. This pattern aligns with Kevin’s role as CFO, though the filings provide no insight into the rationale behind these transactions. The data reflects a measured approach to reducing equity exposure in ACRS over time.
AI-assisted summary